Endacea, Inc.
Endacea, Inc. (RTP, NC), an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as drug candidates for a number of medical indications, including: 1) cisplatin-induced renal impairment; 2) acute or worsening renal impairment associated with acute or chronic heart failure; and 3) inflammation, including sepsis and asthma. Endacea is also developing a sensitive and specific biomarker for sepsis.
